AD-218
/ Yuhan Corp
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
February 05, 2025
A Study to Evaluate the Efficacy and Safety of AD-218
(clinicaltrials.gov)
- P3 | N=520 | Recruiting | Sponsor: Addpharma Inc. | Trial completion date: Jun 2025 ➔ Jun 2026 | Trial primary completion date: Mar 2025 ➔ Mar 2026
Trial completion date • Trial primary completion date • Dyslipidemia • Metabolic Disorders • Mixed Hyperlipidemia
February 16, 2024
A Study to Evaluate the Efficacy and Safety of AD-218
(clinicaltrials.gov)
- P3 | N=520 | Recruiting | Sponsor: Addpharma Inc. | Trial completion date: Oct 2024 ➔ Jun 2025 | Trial primary completion date: May 2024 ➔ Mar 2025
Trial completion date • Trial primary completion date • Dyslipidemia • Metabolic Disorders
November 29, 2022
A Study to Evaluate the Efficacy and Safety of AD-218
(clinicaltrials.gov)
- P3 | N=520 | Recruiting | Sponsor: Addpharma Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Dyslipidemia • Metabolic Disorders
June 01, 2022
A Study to Evaluate the Efficacy and Safety of AD-218
(clinicaltrials.gov)
- P3 | N=520 | Not yet recruiting | Sponsor: Addpharma Inc.
New P3 trial • Dyslipidemia • Metabolic Disorders
1 to 4
Of
4
Go to page
1